Jersey Mike’s Clears $1 Billion, but Buyers Set the Terms

Jersey Mike’s gave the week its scale and its clearest read on risk appetite. The sandwich franchisor and its shareholders sold 43.48 million shares at $23, the midpoint of the marketed range, for a $1 billion offering. Yet the stock opened below issue, a restrained handoff that Axios reported on debut day. For a recognizable consumer brand with a top-tier syndicate, midpoint pricing followed by a soft opening is useful evidence: investors funded the transaction, but they did not chase it.

That distinction framed the week. Reformation priced at the floor and opened flat. Apnimed increased its deal and reached the top of range, while Attovia advanced toward an early-August launch. Scribe Therapeutics, which priced the prior week and closed this week, remained the counterexample: a smaller, upsized biotech offering that produced a strong first session. The calendar was open, though allocation depended heavily on issuer quality and terms.

Jersey Mike’s: a large deal with limited fresh capital

The headline size overstates the capital entering the company. Jersey Mike’s sold about 13.78 million shares, while existing holders sold about 29.70 million. In other words, roughly 68% of the base deal was secondary. The company’s final prospectus sets out the $23 price and the split between issuer and selling-holder shares. The issuer’s gross proceeds were therefore about $317 million, far below the $1 billion transaction value.

The proceeds still matter because the company entered the offering with substantial leverage. Jersey Mike’s had about $2.1 billion of debt and $232 million of cash before the IPO, according to a review of its offering documents. The prospectus directs issuer proceeds through an organizational transaction that ultimately supports debt repayment and general corporate purposes. IPOGrid reads this as a balance-sheet assist wrapped inside a much larger liquidity event for existing owners.

The operating business gives buyers something concrete to underwrite. Jersey Mike’s generated $724 million of 2025 revenue, up about 11%, and $55 million of net income, versus $653 million and $5 million in 2024, as reported from the registration statement. Its franchised model and more than 3,300 locations provide scale, while management told Axios it sees room for at least 7,500 U.S. stores. The reviewer’s concern is that the IPO asked public buyers to accept sponsor ownership, leverage and a large secondary component at once. The below-price opening showed that brand recognition did not erase those terms.

Reformation clears at the floor

Reformation sold 14.06 million shares at $15, the bottom of its $15 to $17 range, raising $210.9 million in the offering. The final prospectus confirms the print. Of the marketed shares, 9.48 million came from the company and 4.58 million from existing shareholders, according to the issuer’s launch release.

The apparel brand brought credible growth and weaker profit conversion. Revenue rose to $507.1 million in 2025 from $438.2 million, while net income fell to $12.6 million from $33 million, according to Reuters’ filing review. Most issuer proceeds were earmarked for debt repayment, including roughly $125 million against a term loan at the midpoint assumptions. Our interpretation is that floor pricing and a flat opening were a disciplined outcome for a sponsor-backed consumer issuer whose growth story arrived alongside declining earnings and debt cleanup.

Biotech takes the higher-beta slot

Apnimed increased its offering from 10 million to 12 million shares and priced at $16, the top of its $14 to $16 range, raising $192 million. The final terms appear in its 424B4 prospectus. The company is effectively financing the regulatory and commercial bridge for Oxnimbi, its oral obstructive sleep apnea candidate. Earlier marketing contemplated net proceeds of $134.6 million on the original base deal, and Fierce Biotech detailed the approval-driven financing need. The upsizing is a real demand signal, but IPOGrid would frame the risk as binary and clinical: the value proposition remains tied to FDA review and launch execution.

Attovia Therapeutics moved closer to market with an amended registration statement and exchange registration. It proposed 12.5 million shares at $15 to $17, or $200 million at the midpoint, led by Morgan Stanley, Leerink, Citi and RBC. Its amended S-1 describes a clinical-stage pipeline led by ATTO-1310 and the usual approval, development and commercialization uncertainties. The deal was positioned for the following week, so the relevant signal was readiness, not a completed book.

Scribe supplied the better biotech precedent. It had priced an upsized 8.58 million-share IPO at $15, raised $128.7 million, and sold another 500,000 shares to Sanofi in a concurrent private placement, according to the company’s pricing release. Shares opened at $25 and finished their first day at $21.65, up 44.3%, BioWorld reported. That performance likely helped keep the window open for Apnimed and Attovia, though it does not reduce their asset-specific risk.

A small-cap caution

IMC Rare Earths priced 4 million shares at $5 for a $20 million IPO, while a separate resale prospectus covered 6.1 million selling-holder shares. The company’s IPO prospectus describes an exploration-stage Brazilian project with no operating mines or revenue, and the resale prospectus makes clear that the issuer receives no proceeds from those secondary sales. IPOGrid reads the pairing as a caution flag: public-market access arrived before operating proof, with additional saleable supply visible from the outset.

The week therefore ended with breadth rather than exuberance. A billion-dollar consumer name got done, apparel cleared at the floor, and biotech attracted capital where books could be upsized. The common message was price discipline. Investors accepted new issuance, then used opening trades to remind sponsors and issuers that completion and endorsement remain separate judgments.